Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
CFB Client Secures $3M Public and Private Investment
November 14, 2017
Codagenix, Inc., a clinical stage, venture and public-sector-funded small business, announced it has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH.
The public funding to Codagenix is via a Phase II SBIR grant for $1.5M to support the pre-clinical manufacturing of the vaccine candidate. The private funding of $1.5M was provided by TopSpin Partners to support a Phase I trial to demonstrate safety and immunogenicity in aged volunteers. The two funding source were not linked; however, both are dedicated to supporting Codagneix’s RSV vaccine through a Phase I trial. Clinical Trial material of Codagenix RSV Vaccine candidate is currently being manufactured with a Phase I targeted for Q3- or Q4-2018.
“Codagenix is an incredible example of a company rooting in our expanding bioecosystem, growing from a startup out of Stony Brook University into a clinical stage company” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is proud to provide ongoing support for the work they are doing through our various programs including the Applied Research and Development awards and the Long Island Bioscience Hub funding initiatives.
“We are wrapping up a Phase I with our live-attenuated Influenza Vaccine in Q1-2018 and are very much looking forward to adding a second clinical-stage compound to our pipeline with RSV,” stated Codegenix COO J. Robert Coleman. “We are grateful to our investors and partners like the Center for Biotechnology that understand our vision and continually support our development at these early stages. We are demonstrating that our platform provides a rational means to design vaccines against a range targets – yielding candidates suitable for full clinical development.”
Codagenix has raised a total of $10M since 2015 – with its influenza vaccine candidate currently in Phase I and a pre-clinical pipeline that includes Zika, Dengue, and Agricultural targets in addition to RSV.
RSV is a virus that targets newborns and the elderly, with an estimated market size of $2 Billion for a potential RSV vaccine.
About Codagenix Inc.
Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a “disruptive” software-based rational design algorithm that is unlike previous vaccine “platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Zika, Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens.
Codagenix has also been supported the Center for Biotechnology at Stony brook University which is a New York State Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH)
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
The Life Sciences Innovation and Entrepreneurship (LiSIE) program at Stony Brook is looking to give students a jump-start in the bioscience industry. The program is a joint effort between the Department of Biomedical Engineering in the College of Engineering and Applied Sciences, the College of Business and the Center for Biotechnology. “From the lab to leadership”, the program aims to teach key business principles to life sciences students so they’re equipped to work in the business side of science.
Read the recent SBU News feature on the program and the CFB Appointed Director Director of the Program in Life Sciences Innovation and Entrepreneurship, Dr. Louis A. Peña.
[post_title] => Fueling BioEntrepreneurship at Stony Brook University
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fueling-bioentrepreneurship-at-stony-brook-university
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:43:53
[post_modified_gmt] => 2025-02-24 17:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4426
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3301
[post_author] => 3
[post_date] => 2019-07-22 13:14:41
[post_date_gmt] => 2019-07-22 13:14:41
[post_content] => The NIH and CDC have released the annual SBIR Contract Proposal Solicitation (PHS 2020-1), with a submission date of October 23, 2019, 5:00 PM EDT. Please follow the directions in the solicitation very carefully. You must respond exactly to a topic in the solicitation.
A pre-proposal conference, via webinar, will take place on August 7 at 1:00 PM EDT. This informational webinar will discuss the PHS 2020-1 solicitation, electronic contract proposal submission (eCPS) website, clinical trials, and topics.
Please register for HHS SBIR PHS 2020-1 Contract Webinar in advance, here:
https://attendee.gotowebinar.com/register/7505039171902241027
(After registering, you will receive a confirmation email containing information about joining the webinar.)
The following Institutes/Centers have issued research topics in the PHS 2020-1 Solicitation:National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Cancer Institute (NCI)
National Heart, Lung and Blood Institute (NHLBI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Allergy and Infectious Diseases (NIAID)
Centers for Disease Control and Prevention (CDC)
National Center for Chronic Disease and Health Promotion (NCCDPHP)
National Center for Environmental Health (NCEH)
National Center for Emerging Zoonotic and Infectious Diseases (NCEZID)
National Center for Immunization and Respiratory Diseases (NCIRD)
Submission Process: There is an electronic submission process for all proposals. Applicants must use the Contract Proposal Submission (eCPS) website to submit their proposal. No other method of proposal submission is permitted. Instructions for electronic submission are provided in the solicitation.
Please check NOT-OD-19-121 for topics, contracting officer contact information and other details. You can also find the SBIR contract solicitation link on theFunding page and FedBizOpps.
Those interested in the PHS small business research GRANT programs, where investigator-initiated research ideas are encouraged, should use the Omnibus SBIR and STTR solicitations. You can find solicitation links on the Funding page. To understand better the differences between grants and contracts, view the Apply page.
[post_title] => NIH/CDC SBIR Contract Solicitation Now Available
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => nihcdc-sbir-contract-solicitation-now-available
[to_ping] =>
[pinged] =>
[post_modified] => 2019-07-22 13:14:41
[post_modified_gmt] => 2019-07-22 13:14:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3301
[menu_order] => 92
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3099
[post_author] => 3
[post_date] => 2018-12-17 20:28:10
[post_date_gmt] => 2018-12-17 20:28:10
[post_content] => The course is presented in a series of five sequential videos. The video modules and course details can be found here: https://www.nibib.nih.gov/entrepreneurial-finance-course
The National Institutes of Health (NIH) supports the development and commercialization of biomedical technologies through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. With the goal of bringing life-saving innovations to market, NIH SBIR/STTR funding provides early-stage seed capital to US-owned small businesses. While the commercialization of biomedical technologies can require a significant amount of both time and money, rigorous financial planning can help navigate and mitigate risks for small businesses and can enhance chances of success along the pathway to market. For biomedical innovators considering funding through the NIH SBIR/STTR programs (https://sbir.nih.gov), it is imperative to evaluate the use of federal grant funding within the context of a broader financial plan.Course Objectives
The purpose of this course is to present biomedical entrepreneurs with a detailed framework for building a step-wise, validated financial plan. Moving beyond the short-term perspective of immediate financing needs to a comprehensive, long-term financial plan will increase the probability of success for your venture. The primary learning objectives for this course are as follows:
- Understand the importance of financial planning for your small business
- Gain perspective on SBIR/STTR funding within the broader context of your financial plan
- Learn practical approaches to developing a long-term financial plan
- Evaluate the various sources of funding
- Examine the use of comparables in validating your financial plan
[post_title] => Free Course from NIH: Entrepreneurial Finance for Biomedical Innovators
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => free-course-from-nih-entrepreneurial-finance-for-biomedical-innovators
[to_ping] =>
[pinged] =>
[post_modified] => 2018-12-17 20:28:10
[post_modified_gmt] => 2018-12-17 20:28:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3099
[menu_order] => 109
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
